Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant.Â
Axicabtagene ciloleucel, commonly known as axi-cel, is an immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.Â
An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a study shows.
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced an update to the ArteraAI Prostate Test, enabling clinicians to make more informed decisions about active surveillance when delivering care to prostate cancer patients.
A new donor-funded project is offering free assistance to newly-diagnosed cancer patients across Los Angeles County to help them navigate the appointments, tests, options, and challenges that come with a life-altering diagnosis.
Underrepresentation of racial and ethnic minority populations in cancer clinical trials persists partly because translation and interpretation services and resources are unavailable or inadequate in the United States, according to a Children’s Oncology Group study led by Columbia University School of Nursing.
The American Society of Clinical Oncology has brought together 12 groups of cancer care delivery professionals to initiate a program aimed to improve health equity.
Cleveland Clinic-led research has identified geographic areas in the United States where strategic efforts to promote colorectal cancer screening could help reduce health care gaps affecting Hispanic/Latino communities.
People who both vape and smoke are four times more likely to develop lung cancer than people who just smoke, according to a new study published by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and College of Public Health.Â
Positive high-level results from an interim analysis of the AMPLIFY phase III trial showed a fixed duration of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.
